Background Alveolar osteitis (AO) is a poorly understood, common, painful complication following exodontia. It is sometimes managed by inappropriate prescription of antibiotics which contributes to the global threat of antimicrobial resistance. Use of intra‐alveolar chlorhexidine also presents a serious risk of anaphylaxis to the patient. Objective This scoping review aims to investigate the aetiology, prevention and management of AO and highlight the extent of inappropriate prescribing and intra‐alveolar chlorhexidine use. Design A scoping review was undertaken using the PRISMA guidelines. Medline, Ovid and Pubmed were searched between 2010 and 2020, from which 63 studies were selected for review that related to the aetiology, prevention or management of AO. Data were analysed for frequency of studies reporting information on risk factors for aetiology, prevention strategies and management including inappropriate management using antibiotic prescribing and intra‐alveolar chlorhexidine. Results Impaired immune response, surgical technique and age were identified as significant factors in the development of AO, while there is conflicting evidence regarding the effects of smoking and gender. With regard to prevention, the use of prophylactic antibiotics is not supported within the literature. Saline irrigation and eugenol pastes used preventively have been shown to be cheap and effective alternatives to chlorhexidine with no adverse effects. Hyaluronic acid and low‐level laser therapies showed a significant reduction in pain and soft‐tissue inflammation in the management of AO compared to Alveogyl. Conclusions Further understanding of the pathophysiology of AO is needed, in addition to large high‐quality RCTs or long‐term observational studies into the aetiology, prevention, and management of AO to produce up‐to‐date evidence‐based clinical guidelines. Clinicians should also be mindful of their contribution to growing antimicrobial resistance and avoid inappropriate prescribing of antibiotics. Saline should replace chlorhexidine as the intra‐alveolar irrigant of choice.